
Mirvetuximab Soravtansine
OncoPharm
00:00
Efficacy: Response Rates from Study 417
John asks about trial results and reports the phase 2 study showed about 32% overall response rate, mostly partial responses.
Play episode from 13:36
Transcript

John asks about trial results and reports the phase 2 study showed about 32% overall response rate, mostly partial responses.